re-vana-therapeutics-logo-square

The judges were impressed by OcuLief, a biodegradable platform delivered as a liquid through a 25G needle that forms implants of up to 60mg in situ for sustained, controlled delivery of therapeutics to the posterior segment of the eye. This innovative app

Michael O'Rourke and Mark Lee, Deputy Minister for Department of Economy Patrick Ruane, Re-Vana COO Re-Vana Lab Re-Vana Guests Michael O'Rourke, Re-Vana CEO James Murray, Re-Vana BOD Friday the 20th of March was a fantastic evening celebrating an importan

Join us in Northern Ireland, where healthcare companies are advancing new technologies that are improving medicine and quality of life around the world. From 3D surgical planning and innovative ophthalmic drug delivery to cutting-edge cancer diagnostics,

Article by: David Wild Citeline IN VIVO Boehringer Strengthens Partner Ecosystem To Drive Early Ophthalmology Innovation_In Vivo ArticleDownload The post Boehringer Strengthens Partner Ecosystem To Drive Early Ophthalmology Innovation appeared first on Re

Excerpt from Wall Street Journal VC Daily Re-Vana, Boehringer Strike Deal for Gentler Eye-Disease Treatments By Brian Gormley, WSJ Pro Good day. Eye injections are a fact of life for many patients with severe ocular diseases. In a new partnership, Re-Vana

The partnership strengthens the University's reputation as a leading UK university for commercialisation of research and nurturing spin-outs capable of global impact. A spin-out from Queen's University - Re-Vana Therapeutics - has signed a major collabora

Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK 28 July 2025 - Boehringer Ingelheim and

The post New Re-Vana technology animation demonstrates EyeLief and OcuLief delivering sustained release biologics. appeared first on Re-Vana.

RE-Vana Therapeutics CEO Michael J. O'Rourke announces two new team appointments: Following our successful $11.9M Series A in November 2022, Re-Vana Therapeutics is delighted to further strengthen our team with two new appointments as we develop our susta

Visionary Ventures Leads Financing Round to Support the Development of Sustained Release Ophthalmic Therapeutics BELFAST, Northern Ireland, Nov. 30, 2022 /PRNewswire/ - Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company developing